Search Result

Results for "

glucose kinase

" in MedChemExpress (MCE) Product Catalog:

By Targets:	AMPK (3) Apoptosis (2) Endogenous Metabolite (7) Free Fatty Acid Receptor (1) Glucokinase (3) PDHK (2) PKC (1) Potassium Channel (1)
By Research Areas:	Cancer (4) Cardiovascular Disease (3) Endocrinology (1) Infection (1) Inflammation/Immunology (3) Metabolic Disease (14) Neurological Disease (2)

Inhibitors & Agonists

Screening Libraries

Peptides

Natural
Products

Isotope-Labeled Compounds

Targets Recommended: GLUT SGLT

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-131940

3-O-Methyl-N-acetyl-D-glucosamine 3-O-Methyl-GlcNAc	Others	Metabolic Disease
3-O-Methyl-N-acetyl-D-glucosamine is a potent inhibitor of N-acetylglucosamine kinase. 3-O-Methyl-N-acetyl-D-glucosamine potently inhibits glucose phosphorylation by N-acetylglucosamine kinase whereas glucokinase is not at all affected by this hexosamine .

HY-148189

Aldometanib 3 Publications Verification LXY-05-029	AMPK	Metabolic Disease
Aldometanib (LXY-05-029) is an orally active aldolase inhibitor. Aldometanib can activate lysosomal adenosine monophosphate-activated protein kinase (AMPK) and decreases blood glucose. Aldometanib can be used for the research of metabolic homeostasis .

HY-P1401

Protein Kinase C (19-36)	PKC	Metabolic Disease
Protein Kinase C (19-36) is a pseudosubstrate peptide inhibitor of *protein kinase* C (PKC), with an IC₅₀** of 0.18 μM. Protein Kinase C (19-36) markedly attenuated vascular hyperproliferation and hypertrophy as well as glucose-induced suppression of natriuretic peptide receptor response .

HY-E70032

N-Acetylhexosamine kinase (NahK)	Endogenous Metabolite	Metabolic Disease
N-Acetylhexosamine kinase (NahK) is an anomeric kinase acting on a glucose-type substrate. N-Acetylhexosamine kinase catalyzes the phosphorylation of GlcNAc or GalNAc at the anomeric C1 position with ATP to form N-acetylhexosamine 1-phosphate (GlcNAc-1P/GalNAc-1P) .

HY-128578

KPLH1130	PDHK	Metabolic Disease Inflammation/Immunology
KPLH1130 is a specific pyruvate dehydrogenase kinase (PDK) inhibitor, blocks macrophage polarization and attenuates proinflammatory responses. KPLH1130 improves glucose tolerance in HFD-fed mice .

HY-N6258

Kahweol	AMPK Apoptosis	Metabolic Disease
Kahweol is one of the consituents of the coffee from Coffea Arabica with anti-inflammatory anti-angiogenic, and anti-cancerous activities. Kahweol inhibits adipogenesis and increase glucose uptake by AMP-activated protein kinase (AMPK) activation. Kahweol induces apoptosis.

HY-P3257B

ADP-Specific glucokinase, thermococcus litoralis ADP-Dependent hexokinase, thermococcus litoralis	Glucokinase	Neurological Disease Metabolic Disease Cancer
ADP-Specific glucokinase, thermococcus litoralis is an ADP-specific **glucose kinase** expressed in thermophilic archaea. ADP-Specific glucokinase, thermococcus litoralis can catalyze glucose into glucose-6-phosphate, which promotes glycolysis. ADP-Specific glucokinase, thermococcus litoralis can activate T cells and enhance the phagocytic activity of macrophages. ADP-Specific glucokinase, thermococcus litoralis can be used in research on metabolic diseases, neurological disorders, and tumors .

HY-P3257A

ADP-specific glucokinase, pyrococcus furiosus ADP-dependent hexokinase, pyrococcus furiosus	Glucokinase	Neurological Disease Metabolic Disease Cancer
ADP-Specific glucokinase, pyrococcus furiosus is an ADP-specific **glucose kinase** expressed in thermophilic archaea. ADP-Specific glucokinase, pyrococcus furiosus can catalyze glucose into glucose-6-phosphate, which promotes glycolysis. ADP-Specific glucokinase, pyrococcus furiosus can activate T cells and enhance the phagocytic activity of macrophages. ADP-Specific glucokinase, pyrococcus furiosus can be used in research on metabolic diseases, neurological disorders, and tumors .

HY-125863A

Glucose-6-phosphate dehydrogenase (Leuconostoc sp., recombinant) G6PD (Leuconostoc sp., recombinant)	Endogenous Metabolite	Metabolic Disease
Glucose-6-phosphate dehydrogenase (Leuconostoc sp., recombinant) is an NADP-dependent enzyme in the pentose phosphate pathway, which is one of the ways glucose is metabolized. Glucose-6-phosphate dehydrogenase (Leuconostoc sp., recombinant) can be used to quantify ATP, glucose, and creatine kinase .

HY-162586

PDHK-IN-7	Others	Cancer
PDHK-IN-7 (compound 32) is an inhibitor of pyruvate dehydrogenase kinase with an IC₅₀ value of 17 nM.PDHK-IN-7 activates PDH in rat livers and has a glucose-lowering effect in Zucker fatty rats .

HY-126585

SAICAR 1 Publications Verification	Endogenous Metabolite	Cancer
SAICAR is an intermediate of de novo purine nucleotide biosynthesis, activates *pyruvate kinase* isoform M2 (PKM2) in an isozyme-selective manner, with an EC₅₀** of 0.3 mM. SAICAR stimulates PKM2 and promotes cancer cell survival in glucose-limited conditions .

HY-N6258R

Kahweol (Standard)	AMPK Apoptosis	Metabolic Disease
Kahweol (Standard) is the analytical standard of Kahweol. This product is intended for research and analytical applications. Kahweol is one of the consituents of the coffee from Coffea Arabica with anti-inflammatory anti-angiogenic, and anti-cancerous activities. Kahweol inhibits adipogenesis and increase glucose uptake by AMP-activated protein kinase (AMPK) activation. Kahweol induces apoptosis.

HY-126585S

SAICAR-d1	Endogenous Metabolite	Metabolic Disease
SAICAR-d is the deuterium labeled SAICAR. SAICAR is an intermediate of de novo purine nucleotide biosynthesis, activates pyruvate kinase isoform M2 (PKM2) in an isozyme-selective manner, with an EC50 of 0.3 mM. SAICAR stimulates PKM2 and promotes cancer cell survival in glucose-limited conditions[1][2].

HY-136631

PF-04279405	Glucokinase	Metabolic Disease
PF-04279405 is a potent and full-acting glucokinase (GK) agonist (EC₅₀=23 nM). Glucokinase (GK) is an enzyme responsible for the conversion of glucose to glucose-6-phosphate and plays a key role in maintaining blood glucose homeostasis. PF-04279405 can be used in the research of type 2 diabetes .

HY-Y1069R

(S)-Malic acid (Standard)	Endogenous Metabolite	Metabolic Disease
(S)-Malic acid (Standard) is the analytical standard of (S)-Malic acid. This product is intended for research and analytical applications. (S)-Malic acid ((S)-2-Hydroxysuccinic acid) is a dicarboxylic acid in naturally occurring form, contributes to the pleasantly sour taste of fruits and is used as a food additive. In Vitro: It is showed that ME is essential for (S)-2-Hydroxysuccinic acid (L-malic acid) utilization in L. casei. Furthermore, deletion of either the gene encoding the histidine kinase or the response regulator of the TC system resulted in the loss of the ability to grow on (S)-2-Hydroxysuccinic acid, thus indicating that the cognate TC system regulates and is essential for the expression of ME. Transcriptional analyses shows that expression of maeE is induced in the presence of (S)-2-Hydroxysuccinic acid and repressed by glucose, whereas TC system expression is induced by (S)-2-Hydroxysuccinic acid and is not repressed by glucose .

HY-15589

GW9508 4 Publications Verification	Free Fatty Acid Receptor Potassium Channel	Cardiovascular Disease Metabolic Disease Inflammation/Immunology
GW9508 is a potent and selective G protein-coupled receptors FFA1 (GPR40) and GPR120 agonist with pEC₅₀s of 7.32 and 5.46, respectively. GW9508 shows ~100-fold selectivity for GPR40 over GPR120. GW9508 is inactive against other GPCRs, kinases, proteases, integrins and PPARs. GW9508 is a glucose-sensitive insulin secretagogue and an ATP-sensitive potassium (K_ATP) channels opener. Anti-inflammatory and anti-atherosclerotic activities .

HY-121744

PS10 2 Publications Verification	PDHK	Inflammation/Immunology
PS10 is a novel, potent and ATP-competitive pan-PDK inhibitor, inhibits all PDK isoforms with IC₅₀ of 0.8 μM, 0.76 μM, 2.1 μM and 21.3 μM for PDK2, PDK4, PDK1, and PDK3, respectively. PS10 shows high affinity for PDK2 (K_d= 239 nM) than for Hsp90 (K_d= 47 μM) . PS10 improves glucose tolerance, stimulates myocardial carbohydrate oxidation in diet-induced obesity. PS10 has the potential for the investigation of diabetic cardiomyopathy .PDK: pyruvate dehydrogenase kinase

HY-155156

PF-07238025	Endogenous Metabolite	Cardiovascular Disease
PF-07238025 is a BCKDC kinase (BDK) inhibitor (EC₅₀=19 nM). PF-07238025 stabilizes the interaction between BDK and BCKDH core subunit E2 and prevents phosphorylation of E1. While BDK mediates branched-chain ketoacid dehydrogenase (BCKDH) phosphorylation, and inhibition of BCKDH is involved in controlling the rate-limiting step of branched-chain amino acid (BCAA) degradation. Impaired BCAA catabolism has been associated with several diseases, particularly cardiometabolic diseases, including heart failure (HF), type 2 diabetes mellitus (T2DM), non-alcoholic fatty liver disease (NAFLD), and obesity. PF-07238025 improved cardiometabolic endpoints and improves glucose tolerance in mice .

HY-155157

PF-07247685	Endogenous Metabolite	Cardiovascular Disease
PF-07247685 is a BCKDC kinase (BDK) inhibitor (EC₅₀=2.2 nM). PF-07247685 stabilizes the interaction between BDK and BCKDH core subunit E2 and prevents phosphorylation of E1. While BDK mediates branched-chain ketoacid dehydrogenase (BCKDH) phosphorylation, and inhibition of BCKDH is involved in controlling the rate-limiting step of branched-chain amino acid (BCAA) degradation. Impaired BCAA catabolism has been associated with several diseases, particularly cardiometabolic diseases, including heart failure (HF), type 2 diabetes mellitus (T2DM), non-alcoholic fatty liver disease (NAFLD), and obesity. PF-07247685 improved cardiometabolic endpoints and improves glucose tolerance in mice .

HY-106024A

Alagebrium bromide ALT711 bromide	Others	Infection
Alagebrium bromide is a cross-link breaker. This study investigated the role of advanced glycation end products (AGEs) in mediating protein kinase C (PKC) isoform expression in diabetic nephropathy. In vitro, vascular smooth muscle cells cultured in high glucose (25-mmol/l) showed increased translocation and expression of PKC-α compared with cells cultured in low glucose (5-mmol/l). Coculture with ALT-711 more effectively attenuated the increased expression and translocation of PKC-α compared with aminoguanidine, an inhibitor of AGE formation. Streptozotocin-induced diabetic rats were randomized to no treatment, ALT-711 treatment, or aminoguanidine treatment. Diabetes induced an increase in PKC-α as well as -βI, -βII, and -ε isoforms. ALT-711 and aminoguanidine treatment, both of which attenuated renal AGE accumulation, abolished these increases in PKC expression. However, only ALT-711 reduced the translocation of phosphorylated PKC-α from the cytoplasm to the membrane. ALT-711 treatment attenuated the expression of vascular endothelial growth factor (VEGF) and extracellular matrix proteins (fibronectin and laminin) and was associated with a reduction in albuminuria. Aminoguanidine had no effect on VEGF expression, although a reduction in fibronectin and laminin was observed. These findings suggest that AGEs are important stimulators of PKC activation, particularly PKC-α, in patients with diabetic nephropathy, which can be directly inhibited by ALT-711.

Cat. No.	Product Name

HY-L092

Glucose Metabolism Compound Library	1,073 compounds
Glucose homeostasis is tightly regulated to meet the energy requirements of the vital organs and maintain an individual’s health. Glucose metabolism includes glycolysis, tricarboxylic acid cycle, pentose phosphate pathway, oxidative phosphorylation and other metabolic pathways. Glucose is the major carbon source that provides the main energy for life. Glucose metabolism dysregulation is also implicated in many diseases such as diabetes, heart disease, neurodegenerative diseases and even cancer. MCE offers a unique collection of 1,073 compounds related to glucose metabolism, which target glucose metabolism related targets, such as GLUT, Hexokinase, Pyruvate Kinase, IDH, etc. MCE glucose metabolism library is a powerful tool for studying glucose metabolism and drug discovery of diseases related to glucose metabolism.

Glucose Metabolism Compound Library

1,073 compounds

Glucose homeostasis is tightly regulated to meet the energy requirements of the vital organs and maintain an individual’s health. Glucose metabolism includes glycolysis, tricarboxylic acid cycle, pentose phosphate pathway, oxidative phosphorylation and other metabolic pathways. Glucose is the major carbon source that provides the main energy for life. Glucose metabolism dysregulation is also implicated in many diseases such as diabetes, heart disease, neurodegenerative diseases and even cancer.

MCE offers a unique collection of 1,073 compounds related to glucose metabolism, which target glucose metabolism related targets, such as GLUT, Hexokinase, Pyruvate Kinase, IDH, etc. MCE glucose metabolism library is a powerful tool for studying glucose metabolism and drug discovery of diseases related to glucose metabolism.

HY-L058

Glycolysis Compound Library	740 compounds
Glycolysis is a series of metabolic processes by which one molecule of glucose is catabolized to two molecules of pyruvate with a net gain of two ATP. Glycolysis takes place in 10 steps and catalyzed by a series of enzyme, such as hexokinase, Glucose-6-phosphate isomerase, Phosphofructokinase, etc. Glycolysis is used by all cells in the body for energy generation. Most cancer cells exhibit increased glycolysis and use this metabolic pathway for generation of ATP as a main source of their energy supply. This phenomenon is known as the Warburg effect and is considered as one of the most fundamental metabolic alterations during malignant transformation. Because increased aerobic glycolysis is commonly seen in a wide spectrum of human cancers, development of novel glycolytic inhibitors as a new class of anticancer agents is likely to have broad therapeutic applications. MCE provides a unique collection of 740 glycolysis compounds that mainly target hexokinase, glucokinase, enolase, pyruvate kinase, PDHK, etc. MCE Glycolysis Compound Library is a useful tool for glucose metabolism research and anti-cancer drug discovery.

Glycolysis Compound Library

740 compounds

Glycolysis is a series of metabolic processes by which one molecule of glucose is catabolized to two molecules of pyruvate with a net gain of two ATP. Glycolysis takes place in 10 steps and catalyzed by a series of enzyme, such as hexokinase, Glucose-6-phosphate isomerase, Phosphofructokinase, etc. Glycolysis is used by all cells in the body for energy generation.

Most cancer cells exhibit increased glycolysis and use this metabolic pathway for generation of ATP as a main source of their energy supply. This phenomenon is known as the Warburg effect and is considered as one of the most fundamental metabolic alterations during malignant transformation. Because increased aerobic glycolysis is commonly seen in a wide spectrum of human cancers, development of novel glycolytic inhibitors as a new class of anticancer agents is likely to have broad therapeutic applications.

MCE provides a unique collection of 740 glycolysis compounds that mainly target hexokinase, glucokinase, enolase, pyruvate kinase, PDHK, etc. MCE Glycolysis Compound Library is a useful tool for glucose metabolism research and anti-cancer drug discovery.

Cat. No.	Product Name	Target	Research Area